For pediatric patients with PIK3CD mutation-related immunodeficiency disease with posaconazole, the concentrations from dosages of 0.02 mg/kg/day sirolimus were all within the treatment window, and there was no value exceeding the upper limit of the target concentration. This evidence concerns the gene PIK3CD and immunodeficiency disease.